Sage Therapeutics Inc. said 73 percent of patients with super-refractory status epilepticus (SRSE) who were treated with SAGE-547, its allosteric modulator of synaptic and extra-synaptic GABAA receptors, were successfully weaned from medication keeping them in medically induced comas to prevent persistent seizure.